RBC Capital lowered the firm’s price target on Select Medical (SEM) to $19 from $20 and keeps an Outperform rating on the shares. The stock declined about 7% on Friday after the company reported a Q4 adjusted EBITDA miss and softer-than-expected 2026 guidance, though the firm is encouraged that management does not expect a material headwind related to the high-cost outlier threshold within its CIRH segment in 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM:
- AI-Driven Third-Party Systems Pose Growing Operational and Data Risks for Select Medical
- Select Medical Balances Growth With Margin Pressures
- Select Medical Declares Quarterly Dividend Amid Solid Results
- Select Medical reports Q4 adjusted EPS 16c, consensus 23c
- Select Medical sees 2026 EPS $1.22-$1.32, consensus $1.31